Stem-cell exhaustion, read in the blood: what clonal haematopoiesis reveals
As blood stem cells age, mutant clones take over. By the eighth decade this shows up in about one person in ten — and it tracks with higher mortality and heart disease.
For how we live.
Healthspan, aging biology, and the claims the anti-aging market makes.
As blood stem cells age, mutant clones take over. By the eighth decade this shows up in about one person in ten — and it tracks with higher mortality and heart disease.
Finnish cohorts link regular sauna bathing to lower cardiovascular and all-cause mortality, with a dose-response. But these are observational studies, and no randomised trial has tested sauna against death.
Losing the ability to walk is a turning point in later life. In a large randomised trial, structured activity cut the rate of major mobility disability — evidence that movement protects independence, read honestly.
Failing mitochondria are one of ageing's core hallmarks, and human trials of mitochondria-targeted compounds show flickers of benefit — but the strongest endpoints keep coming back null.
Observational studies tie hearing loss to faster mental decline. But the first large randomised trial found no overall benefit from hearing aids over three years — with a signal of help only in higher-risk older adults.
A prominent hypothesis holds that ageing is lost epigenetic information that can be reset. The mouse experiments behind it are striking, but no human study shows resetting the epigenome extends life.
Cellular senescence is a well-evidenced driver of ageing in animals. The first human trials of senolytic drugs that clear these cells are real but tiny, early, and nowhere near proving longer healthy life.
Even frail people in their 80s and 90s roughly doubled their strength in ten weeks of training. But muscle size barely moved — the honest expectation is a big gain in function and a modest one on the scale.
A landmark trial pushed blood pressure hard and cut mild cognitive impairment — but its headline dementia result fell short of significance after the study stopped early. The pooled trial evidence is real, and modest.
Mouse studies claimed one circulating protein reversed ageing of the heart, muscle and brain. A second team found the muscle effect ran the opposite way — and no human trial has ever tested it.
ASPREE randomised 19,114 healthy older adults to low-dose aspirin or placebo. It made no difference to disability-free survival, and modestly raised deaths and major haemorrhage.
A large treadmill cohort found the least-fit adults had about five times the death rate of the fittest — a bigger risk than coronary disease, smoking or diabetes. But it measures a state, not a lever.
A harmonised meta-analysis of over a million adults found high sitting time raised mortality — but about 60 to 75 minutes a day of activity erased that risk. Being inactive, not the chair itself, did most of the damage.
In 2,292 older adults, weak quadriceps tracked with higher mortality — but muscle size, measured by CT and DXA, did not. The finding reshaped how sarcopenia is defined and moved the target from bulk to strength.
A widely cited cohort found people with diabetes on metformin outlived matched non-diabetic controls. It fuelled the TAME anti-ageing trial — but the human signal is observational, and TAME is not running.
The idea that anti-ageing advances will soon add more than a year of life for every year that passes is popular in longevity circles. National death records point the other way.
A protein named after a Greek fate slows ageing in mice and sharpens memory in old monkeys. In people the evidence is a gene variant you are born with, not a treatment.
For 70 years the idea that oxidative damage drives ageing justified a supplement industry. Large randomised trials found antioxidant pills do not extend life, and some raise mortality.
One cohort tied high animal protein in midlife to higher mortality, yet found the opposite after 65. Guidelines urge older adults to eat more, and plant protein looks best. No trial proves a lifespan effect.
Observational studies robustly link the diet to lower mortality. The best randomised trial measured fewer heart attacks and strokes, and the strongest review finds the evidence for a survival benefit weak.
Large cohorts link higher optimism and a stronger sense of purpose to longer life and lower mortality, in a dose-dependent way. But the studies are observational, and no trial has proved the causal arrow.
Sugars bond to proteins to form advanced glycation end products that accumulate with age and stiffen tissue. Low-AGE diets nudge metabolic markers, but no trial shows they slow ageing.
Meta-analyses of more than a million people find a U-shaped link between sleep duration and death, lowest around seven hours. But this is observational, and reverse causation is the hard part to rule out.
Immunosenescence, the age-related decline of immunity, is real: the thymus shrinks and the T-cell repertoire narrows. The proven counter is not a supplement but vaccines engineered to force a response.
The idea that a little stress makes the body stronger is sound biology, and the best-evidenced example is ordinary exercise. Stretched to cold, fasting and antioxidant pills, the human evidence thins fast.
Autophagy is the cell's self-clearing recycling process, and it wanes with age. Fasting, spermidine and rapamycin switch it on in lab animals — whether that extends human life is unproven.
The rise in chronic, low-grade inflammation with age is genuine, and researchers built a clock from it. The one large trial that lowered inflammation for a hard outcome treated heart disease, not ageing.
Eligibility set by exact date of birth created a natural experiment. Vaccinated people had a 20% lower relative risk of dementia over seven years. It is one striking study, and it tested the older live vaccine.
Forgetting a name is not dementia, and a third of people diagnosed with mild cognitive impairment revert to normal. But that diagnosis still carries weight: risk of dementia stays elevated even in those who bounce back.
The DO-HEALTH sub-study is the first randomised evidence that a supplement can nudge DNA-methylation ageing clocks. The effect was tiny, and the parent trial found no benefit on health outcomes that matter.
The signalling that builds muscle in youth appears to speed ageing and cancer. People with lifelong GH deficiency avoid both — and GH given to healthy older adults raises harms without extending life.
Epigenetic clocks estimate a 'biological age' from DNA methylation. A 2022 study found technical noise alone could shift the result by up to 9 years between replicates of the same sample.
The only long randomised trial of calorie restriction in non-obese adults improved cardiometabolic risk and modestly slowed one measure of biological ageing. Participants never hit the 25% target.
Dietary spermidine tracks with markedly lower mortality in one population study. The first year-long randomised trial of a spermidine supplement found no effect on memory.
The Sardinian 'Blue Zone' was a real, carefully validated finding. A separate line of work argues the world's longevity hotspots track missing birth records and old-age poverty — not diet.
Infusing plasma from young donors is sold as rejuvenation. The mouse work suggests diluting old blood may matter more than adding young blood — and regulators warn the paid infusions have no proven benefit.
The dream was 'compression of morbidity' — sickness squeezed into a short window before death. Across 183 countries the healthspan–lifespan gap instead grew to 9.6 years, and to 12.4 in the US.
Five-day fasting cycles improve risk markers and one 'biological age' estimate in small trials. No human study has yet shown the diet prevents disease or extends life.
In 34,485 older adults, each 0.1 m/s of walking speed tracked with better survival. At age 75, predicted 10-year survival ran from 19% to 91% across the range — but speed reflects health, not the reverse.
No pill in the anti-ageing market has mortality data like physical activity. The largest cohorts show most of the benefit arrives at half the recommended dose, and more brings diminishing returns.
A 2013 paper named nine hallmarks of aging; a 2023 update made it twelve. The framework is the field's shared map — but critics argue it describes ageing without explaining it.
Very long life carries real genetic signals — the APOE gene most robustly, FOXO3 in some populations. But pedigree studies put the true heritability of human lifespan well below 10%.
The NAD+ precursors sold to slow ageing reliably raise NAD+ and are well tolerated. What the randomised trials do not show is a benefit to muscle, metabolism or how old you are.
It extends life in yeast, worms and flies, and in mice on a high-fat diet. In people it fails to reliably switch on the enzyme it targets, and higher intake tracks no drop in death, cancer or heart disease.
The length of your chromosome caps is a noisy population-level marker, not a personal verdict — and genetically longer telomeres raise the risk of several cancers, not lower it.